Positive 5-Year Results for Gefitinib Combo in EGFR-Variant Lung Cancer
At a median 5-year follow-up, patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer (NSCLC) who added chemotherapy to gefitinib continued to have strong progression-free survival (PFS) and overall survival (OS) compared …